Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 16:2022:6745954.
doi: 10.1155/2022/6745954. eCollection 2022.

Factors Associated with Late Local Radiation Toxicity after Post-Operative Breast Irradiation

Affiliations

Factors Associated with Late Local Radiation Toxicity after Post-Operative Breast Irradiation

M C T Batenburg et al. Breast J. .

Abstract

Purpose: To assess determinants associated with late local radiation toxicity in patients treated for breast cancer.

Methods: A systematic review was performed. All studies reporting ≥2 variables associated with late local radiation toxicity after treatment with postoperative whole breast irradiation were included. Cohort studies, randomized controlled trials, and cross-sectional studies were eligible designs. Study characteristics and definitions of determinants and outcome measures were extracted. If possible, the measure of association was extracted.

Results: Twenty-one studies were included in this review. Six out of seven studies focused on the association between radiotherapy (boost) dose or irradiated breast volume and late radiation toxicity found significant results. Tumor bed boost was associated with late radiation toxicity, fibrosis, and/or edema in six out of twelve studies. Lower age was associated with late breast toxicity in one study, while in another study, higher age was significantly associated with breast fibrosis. Also, no association between age and late radiation toxicity was found in eight out of twelve studies. Similar inconsistent results were found in the association between late radiation toxicity and other patient-related factors (i.e., breast size, diabetes mellitus) and surgical and systemic treatment-related factors (i.e., complications after surgery, chemotherapy, and time between surgery and radiotherapy).

Conclusion: In modern 3D radiotherapy, radiotherapy (boost) dose and volume are-like in 2D radiotherapy-associated with late local radiation toxicity, such as breast fibrosis and edema. Treatment de-escalation, for example, partial breast irradiation in selected patients might be important to decrease late local toxicity without compromising locoregional control and survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of selected studies to evaluate which determinants were associated with late radiation toxicity in breast cancer patients.
Figure 2
Figure 2
Risk of bias assessment for included studies using the quality in prognostic Studies (QUIPS) tool.

References

    1. Netherlands Cancer Registry. Cijfers over kanker. 2020. http://www.cijfersoverkanker.nl .
    1. Runowicz C. D., Leach C. R., Henry N. L., et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. Journal of Clinical Oncology . 2016;34(6):611–635. doi: 10.1200/jco.2015.64.3809. - DOI - PubMed
    1. Fallowfield L., Jenkins V. Psychosocial/survivorship issues in breast cancer: are we doing better? Journal of the National Cancer Institute . 2015;107(1):p. 335. - PubMed
    1. Curran D., van Dongen J. P., Aaronson N. K., et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801. European Journal of Cancer . 1998;34(3):307–314. doi: 10.1016/s0959-8049(97)00312-2. - DOI - PubMed
    1. Mukesh M., Harris E., Jena R., Evans P., Coles C. Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiotherapy and Oncology . 2012;104(1):1–10. doi: 10.1016/j.radonc.2012.04.025. - DOI - PubMed

Publication types